Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

Frost, Sophia; Frayo, Shani; Miller, Brian W.; Orozco, Johnnie J.; Booth, Garrett C.; Hylarides, Mark; Lin, Yukang; Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Back, Tom; Fisher, Darrell R.; Press, Oliver W.

doi:10.1371/journal.pone.0120561

Title: Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

Journal Article · Sun Mar 01 00:00:00 EST 2015 · PLoS One, 10(3):Article No. e0120561

DOI:https://doi.org/10.1371/journal.pone.0120561· OSTI ID:1221461

Frost, Sophia; Frayo, Shani; Miller, Brian W.; Orozco, Johnnie J.; Booth, Garrett C.; Hylarides, Mark; Lin, Yukang; Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Back, Tom; Fisher, Darrell R.; Press, Oliver W.

Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas 90Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with 177Lu. We therefore compared the therapeutic potential of targeting either 90Y or 177Lu to human B-cell lymphoma xenografts in mice.

Cite

Export

Save

Research Organization:: Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)

Sponsoring Organization:: USDOE

DOE Contract Number:: AC05-76RL01830

OSTI ID:: 1221461

Report Number(s):: PNNL-SA-111489

Journal Information:: PLoS One, 10(3):Article No. e0120561, Journal Name: PLoS One, 10(3):Article No. e0120561

Country of Publication:: United States

Language:: English

References (26)

Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Kaminski, Mark S.; Estes, Judith; Zasadny, Kenneth R. Blood, Vol. 96, Issue 4 https://doi.org/10.1182/blood.V96.4.1259	journal	August 2000
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy Goldenberg, David M.; Sharkey, Robert M.; Paganelli, Giovanni Journal of Clinical Oncology, Vol. 24, Issue 5 https://doi.org/10.1200/JCO.2005.03.8471	journal	February 2006
Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies Walter, Roland B.; Press, Oliver W.; Pagel, John M. Cancer Biotherapy and Radiopharmaceuticals, Vol. 25, Issue 2 https://doi.org/10.1089/cbr.2010.0759	journal	April 2010
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity Axworthy, D. B.; Reno, J. M.; Hylarides, M. D. Proceedings of the National Academy of Sciences, Vol. 97, Issue 4 https://doi.org/10.1073/pnas.97.4.1802	journal	February 2000
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin Paganelli, Giovanni; Grana, Chiara; Chinol, Marco European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 4 https://doi.org/10.1007/s002590050397	journal	March 1999
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts Press, Oliver W.; Corcoran, Melissa; Subbiah, Krishnan Blood, Vol. 98, Issue 8 https://doi.org/10.1182/blood.V98.8.2535	journal	October 2001
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas Pagel, John M.; Hedin, Nathan; Subbiah, Krishnan Blood, Vol. 101, Issue 6 https://doi.org/10.1182/blood-2002-03-0874	journal	March 2003
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas Pagel, John M.; Lin, Yukang; Hedin, Nathan Blood, Vol. 108, Issue 1 https://doi.org/10.1182/blood-2005-11-4327	journal	July 2006
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations Pagel, John M.; Orgun, Nural; Hamlin, Donald K. Blood, Vol. 113, Issue 20 https://doi.org/10.1182/blood-2008-11-187401	journal	May 2009
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support Press, Oliver W.; Eary, Janet F.; Appelbaum, Frederick R. New England Journal of Medicine, Vol. 329, Issue 17 https://doi.org/10.1056/NEJM199310213291702	journal	October 1993
A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Press, Oliver W.; Eary, Janet F.; Gooley, Ted Blood, Vol. 96, Issue 9 https://doi.org/10.1182/blood.V96.9.2934	journal	November 2000
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Gopal, Ajay K.; Gooley, Theodore A.; Maloney, David G. Blood, Vol. 102, Issue 7 https://doi.org/10.1182/blood-2003-02-0622	journal	October 2003
Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice Lewis, Michael R.; Zhang, Jiuli; Jia, Fang Nuclear Medicine and Biology, Vol. 31, Issue 2 https://doi.org/10.1016/j.nucmedbio.2003.08.004	journal	February 2004
Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using ¹⁴⁹ Pm, ¹⁶⁶ Ho, and ¹⁷⁷ Lu Mohsin, Huma; Jia, Fang; Bryan, Jeffrey N. Bioconjugate Chemistry, Vol. 22, Issue 12 https://doi.org/10.1021/bc200258x	journal	December 2011
Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies Donnou, Sabrina; Galand, Claire; Touitou, Valérie Advances in Hematology, Vol. 2012 https://doi.org/10.1155/2012/701704	journal	January 2012
An EBV-Genome-Negative Cell Line Established from an American Burkitt Lymphoma; Receptor Characteristics. EBV Infectibility and Permanent Conversion into EBV-Positive Sublines by in vitro Infection Klein, George; Giovanella, Beppino; Westman, Anita Intervirology, Vol. 5, Issue 6 https://doi.org/10.1159/000149930	journal	January 1975
Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) Jadayel, Dm; Lukas, J.; Nacheva, E. Leukemia, Vol. 11, Issue 1 https://doi.org/10.1038/sj.leu.2400555	journal	January 1997
Evaluation of Beta-Absorbed Fractions in a Mouse Model for ⁹⁰ Y, ¹⁸⁸ Re, ¹⁶⁶ Ho, ¹⁴⁹ Pm, ⁶⁴ Cu, and ¹⁷⁷ Lu Radionuclides Miller, William H.; Hartmann-Siantar, Christine; Fisher, Darrell Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, Issue 4 https://doi.org/10.1089/cbr.2005.20.436	journal	August 2005
Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study Alvarez, Ronald D.; Partridge, Edward E.; Khazaeli, M. B. Gynecologic Oncology, Vol. 65, Issue 1 https://doi.org/10.1006/gyno.1996.4577	journal	April 1997
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi Seidl, Christof; Zöckler, Christine; Beck, Roswitha European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 2 https://doi.org/10.1007/s00259-010-1639-2	journal	November 2010
Low-energy Electron Emitters for Targeted Radiotherapy of Small Tumours Acta Oncologica, Vol. 40, Issue 5 https://doi.org/10.1080/028418601750444141	journal	January 2001
Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas Forrer, F.; Oechslin-Oberholzer, C.; Campana, B. Journal of Nuclear Medicine, Vol. 54, Issue 7 https://doi.org/10.2967/jnumed.112.115170	journal	April 2013
Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice Schoffelen, R.; van der Graaf, W. T. A.; Franssen, G. Journal of Nuclear Medicine, Vol. 51, Issue 11 https://doi.org/10.2967/jnumed.110.079376	journal	November 2010
[ ¹⁷⁷ Lu]Pertuzumab: Experimental Therapy of HER-2–Expressing Xenografts Persson, Mikael; Gedda, Lars; Lundqvist, Hans Cancer Research, Vol. 67, Issue 1 https://doi.org/10.1158/0008-5472.can-06-2363	journal	January 2007
Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein Buchsbaum, D. J. Clinical Cancer Research, Vol. 11, Issue 22 https://doi.org/10.1158/1078-0432.ccr-05-0607	journal	November 2005
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma Witzig, Thomas E.; Gordon, Leo I.; Cabanillas, Fernando Journal of Clinical Oncology, Vol. 20, Issue 10 https://doi.org/10.1200/jco.2002.11.076	journal	May 2002

Cited By (6)

A Revisit to the Pretargeting Concept—A Target Conversion Liu, Guozheng Frontiers in Pharmacology, Vol. 9 https://doi.org/10.3389/fphar.2018.01476	journal	December 2018
Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations Siwowska, Klaudia; Guzik, Patrycja; Domnanich, Katharina A. Pharmaceutics, Vol. 11, Issue 8 https://doi.org/10.3390/pharmaceutics11080424	journal	August 2019
Therapeutic Applications of Pretargeting Verhoeven, Marjolein; Seimbille, Yann; Dalm, Simone U. Pharmaceutics, Vol. 11, Issue 9, p. 434 https://doi.org/10.3390/pharmaceutics11090434	journal	September 2019
Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: Preclinical investigations Siwowska, Klaudia; Guzik, Patrycja; Domnanich, Katharina A. ETH Zurich https://doi.org/10.3929/ethz-b-000364088	text	January 2019
Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations Siwowska, Klaudia; Guzik, Patrycja; Domnanich, Katharina A. MDPI Publishing https://doi.org/10.5167/uzh-175813	text	January 2019
Actinide bioimaging in tissues: Comparison of emulsion and solid track autoradiography techniques with the iQID camera Lamart, Stephanie; Miller, Brian W.; Van der Meeren, Anne PLOS ONE, Vol. 12, Issue 10 https://doi.org/10.1371/journal.pone.0186370	journal	October 2017

Similar Records

Comparative efficacy of ¹⁷⁷Lu and ⁹⁰Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

Journal Article · Wed Mar 18 00:00:00 EDT 2015 · PLoS ONE · OSTI ID:1221461

Frost, Sofia H. L.; Frayo, Shani L.; Miller, Brian W.; +11 more

Conventional and Pretargeted Radioimmunotherapy Using Bismuth-213 to Target and Treat Non-Hodgkin Lymphomas Expressing CD20: A Preclinical Model toward Optimal Consolidation Therapy to Eradicate Minimal Residual Disease.

Journal Article · Thu Nov 18 00:00:00 EST 2010 · Blood, 116(20):4231-4239 · OSTI ID:1221461

Park, Steven I; Shenoi, Jaideep; Pagel, John M; +12 more

Anti-CD45 Pretargeted Radioimmunotherapy using Bismuth-213: High Rates of Complete Remission and Long-Term Survival in a Mouse Myeloid Leukemia Xenograft Model

Journal Article · Thu Jul 21 00:00:00 EDT 2011 · Blood · OSTI ID:1221461

Pagel, John M; Kenoyer, Aimee L; Back, Tom; +14 more

Title: Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

Citation Formats

References (26)

Cited By (6)

Similar Records

Related Subjects